Gyre Therapeutics(GYRE) - 2022 Q3 - Quarterly Report

Financial Performance - Catalyst Biosciences reported a net loss of $4.9 million for the three months ended September 30, 2022, compared to a net loss of $25.2 million for the same period in 2021, reflecting a 80.6% improvement [88]. - The company reported a net income of $32.2 million for the nine months ended September 30, 2022, with cash used in operating activities amounting to $31.6 million [111]. - Cash used in operating activities for the nine months ended September 30, 2022 included a net loss of $25.0 million, excluding a net gain of $57.2 million from asset sales [114]. Operating Expenses - Total operating expenses decreased to $5.2 million for the three months ended September 30, 2022, down from $27.5 million in the same period of 2021, a reduction of 81.1% [98]. - Research and development expenses for the three months ended September 30, 2022, were $803,000, a significant decrease of 96% from $20.4 million in the same period of 2021 [95]. - General and administrative expenses decreased by $0.5 million, or 10%, to $4.4 million for the three months ended September 30, 2022, compared to $4.9 million in the same period of 2021 [104]. Cash and Cash Equivalents - As of September 30, 2022, Catalyst's cash and cash equivalents balance was $23.1 million [88]. - As of September 30, 2022, the company had $23.1 million in cash and cash equivalents and an accumulated deficit of $370.5 million [111]. Revenue - Collaboration revenue was $0 for the three months ended September 30, 2022, compared to $2.3 million for the same period in 2021, marking a 100% decline [98]. - License and collaboration revenue was $0 for the three months ended September 30, 2022, due to the termination of the Biogen Agreement [100]. Special Dividends and Future Plans - The company anticipates additional special dividends in the future, following a one-time cash dividend payment of $1.43 per share made on September 20, 2022 [81]. - The company paid a special one-time cash dividend of $1.43 per share, totaling approximately $45.0 million on September 20, 2022 [110]. - The company plans to continue funding operational losses and capital needs through its current cash balance and potential asset sales or collaborations [112]. Research and Development - Catalyst has ceased all research and development activities as of March 2022, which is expected to result in minimal research and development expenses in the next year [96]. - The company is exploring opportunities to license or sell its product candidates, including MarzAA and DalcA, for further development [85][86]. Asset Sales - Cash provided by investing activities was $55.4 million for the nine months ended September 30, 2022, primarily due to $55.0 million from the sale of the complement portfolio to Vertex [117]. - The company received $60 million in cash from Vertex Pharmaceuticals for the sale of its complement portfolio, with $55 million received upfront and $5 million held back for indemnification obligations [83].